Compare
Filana Therapeutics, Inc. vs Camp4 Therapeutics Corp vs Aardvark Therapeutics, Inc. vs Kyntra Bio, Inc.
| Latest fiscal year | Filana Therapeutics, Inc. FLNA | Camp4 Therapeutics Corp CAMP | Aardvark Therapeutics, Inc. AARD | Kyntra Bio, Inc. KYNBRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $3.50M | $0 | n/a |
| Revenue growth (YoY) | n/a | +436.5% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$90.97M | -$80.40M | -$57.59M | $183.45M |
| EPS (Diluted) | -$1.88 | -$2.65 | -$2.93 | $45.37 |
| Operating cash flow | -$32.25M | -$29.55M | -$54.17M | -$4.77M |
| Free cash flow | -$32.83M | -$29.83M | -$54.27M | -$4.81M |
| Cash & equivalents | $95.50M | $109.52M | $47.05M | $47.87M |
| Total assets | $118.36M | $117.81M | $117.18M | $119.59M |
| Total liabilities | $43.95M | $70.10M | $10.55M | $115.12M |
| Shareholders' equity | $74.40M | $47.70M | $106.63M | -$17.00M |
| Return on year-end equity | -122.3% | -168.5% | -54.0% | n/a |
| Shares outstanding | 48.31M | 51.90M | 21.82M | 4.05M |
Revenue, most recent five fiscal years
| Fiscal year | Filana Therapeutics, Inc. | Camp4 Therapeutics Corp | Aardvark Therapeutics, Inc. | Kyntra Bio, Inc. |
|---|---|---|---|---|
| Latest | $41.12M Ended 2013-12-31 | $3.50M Ended 2025-12-31 | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | $10.89M Ended 2012-12-31 | $652.0K Ended 2024-12-31 | n/a | n/a |
| 2 years earlier | $11.48M Ended 2011-12-31 | $350.0K Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | $16.81M Ended 2010-12-31 | n/a | n/a | n/a |
| 4 years earlier | $20.56M Ended 2009-12-31 | n/a | n/a | n/a |